Novo Holdings’ $16.5 billion Catalent buy wins EU antitrust approval
By Foo Yun Chee BRUSSELS (Reuters) -Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any competition issues. Novo Holdings, the controlling shareholder of Danish drugmaker Novo Nordisk, which makes the blockbuster weight-loss drug Wegovy, said …
Novo Holdings’ $16.5 billion Catalent buy wins EU antitrust approval Read More »